CRISPR Discovery of Microprotein Opens New Path in Obesity Treatment

Salk Institute scientists have identified a microprotein that may pave the way for innovative obesity therapies. Using CRISPR gene-editing technology, researchers screened thousands of fat cell genes, uncovering dozens of potential microproteins involved in fat storage and cell growth. Among them, one — named Adipocyte-smORF-1183 — was confirmed to influence lipid droplet formation in fat cells.

Obesity, affecting over a billion people globally, raises the risk of type 2 diabetes, cardiovascular disease, and other conditions. Current treatments, such as lifestyle changes, bariatric surgery, and drugs like GLP-1 analogs, have limitations in access, side effects, and long-term effectiveness.

Microproteins, including GLP-1 itself, are an emerging therapeutic class. The study, published August 7, 2025, in PNAS, highlights CRISPR’s value in uncovering these tiny yet influential molecules. Next steps include testing in human fat cells, with hopes of developing new, targeted obesity treatments based on microprotein biology.

10-08-2025